Who
Christopher Richard Anzalone
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Arrowhead Pharmaceuticals.
In numbers
- Trades disclosed
- 197
- Buys
- 5
- Sells
- 52
- Bought
- $220K
- Sold
- $109.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Jun 2008
- Last trade
- 2 Jan 2026
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 5 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $489K7,416 at $65.88 | filing |
| 2 Jan 2026filed 5 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $383K5,771 at $66.39 | filing |
| 2 Jan 2026filed 5 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $489K7,416 at $65.88 | filing |
| 2 Jan 2026filed 5 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $383K5,771 at $66.39 | filing |
| 29 Dec 2025filed 30 Dec 2025 | ARWR Arrowhead Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,181 at $0.00 | filing |
| 29 Dec 2025filed 30 Dec 2025 | ARWR Arrowhead Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,545 at $0.00 | filing |
| 29 Dec 2025filed 30 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $216K35,181 at $6.15 | filing |
| 29 Dec 2025filed 30 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $102K16,545 at $6.15 | filing |
| 29 Dec 2025filed 30 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.4M35,181 at $69.33 | filing |
| 29 Dec 2025filed 30 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.1M16,545 at $68.69 | filing |
| 22 Dec 2025filed 23 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $684K10,012 at $68.33 | filing |
| 22 Dec 2025filed 23 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $177K2,574 at $68.85 | filing |
| 19 Dec 2025filed 23 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $265K3,979 at $66.67 | filing |
| 19 Dec 2025filed 23 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $554K8,147 at $68.01 | filing |
| 19 Dec 2025filed 23 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $90K1,319 at $68.48 | filing |
| 17 Dec 2025filed 19 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.9M46,287 at $63.55 | filing |
| 17 Dec 2025filed 19 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.3M35,750 at $64.51 | filing |
| 17 Dec 2025filed 19 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $64K982 at $65.53 | filing |
| 17 Dec 2025filed 19 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $131K1,981 at $66.30 | filing |
| 16 Dec 2025filed 16 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $509K8,416 at $60.51 | filing |
News
Head-To-Head Review: DBV Technologies (NASDAQ:DBVT) vs. Arrowhead Pharmaceuticals (NASDAQ:ARWR)ARWR · dailypolitical.com · 21 Oct 2026Arrowhead Pharmaceuticals (NASDAQ:ARWR) versus Sera Prognostics (NASDAQ:SERA) Head to Head ReviewARWR · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Christopher Richard Anzalone; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.